Thursday's Small-Cap Winners & Losers

05/31/07 - 04:48 PM EDT

Sarina Penn

Small-cap stocks leapt higher than the broader market Thursday as several health names ratcheted up on positive news.

Leading the way was Seattle-based Dendreon (DNDN Quote), shares of which soared 27% to $8.55 after the Food and Drug Administration detailed what extra information it will require for approval of the biotech's prostate-cancer vaccine, Provenge.

Also surging on regulatory news was Critical Therapeutics (CRTX Quote), another biotech. Shares of the Lexington, Mass., company traded up 21.4% to $3.23 after the FDA approved for commercialization Zyflo CR, extended-release tablets for asthma treatment. Critical will co-promote the drug with Dey, an affiliate of Germany's Merck GKaA.

Meanwhile Canada-based OccuLogix (OCCX Quote), which makes systems for eye-disease treatment, jumped 15.8% to $1.17 on word it will be taken private by JEGC OCC, a private-equity group ultimately controlled by Occulogix CEO Elias Vamvakas and David Folk of Jefferson Partners.

On or before June 22, JEGC will buy TLCVision's (TLCV Quote) 1.9-million-share Occulogix stake for $1.05 a share -- a slight premium to the stock's latest close price -- and within the next 90 days it will acquire the remainder of the company. TLCVision shares slipped 2 cents to $5.94.

Quantum Fuel Systems Technologies Worldwide (QTWW Quote), based in Irvine, Calif., bounced 22% to $1.78 after its Tecstar Automotive Group struck a deal to provide Force Protection (FRPT Quote) with engineering design and production support for a mine-resistant line of its military vehicles. Terms weren't disclosed. Force Protection shares dropped 6% to $28.47.

< Previous
1 2
Your Recent Quotes: Quote Up0 | Quote Down0
 
Dow S&P 500 NASDAQ
Oil*
61.21
8,359.49
905.84
1,799.73
10 Yr
3.45%
27.81
4.79
6.52
+0.33%
+0.53%
+0.36%
Data delayed 20 min
Get Jim Cramer's Free Newsletter

The Daily Booyah!
Get your daily dose of Cramer in your inbox.
Submit
We respect your privacy.

Premium Stock Ideas
Access Action Alerts Plus to find out Cramer's latest picks now!

Brokerage Partners